The United States healthcare industry is the 3rd largest among all countries. The total worth is over $808 Billion. Recent studies state that US is the 35th healthiest country in the world, indicating clearly that they have the best healthcare companies with unmatched healthcare services/solutions/products. However, in this ever-growing USA landscape, where everything changes in a flick of an eye. It is quite impossible to decide “which are the top healthcare companies in the USA?” To make that “impossible” turn into “I’m possible”, our team extensively researched the USA healthcare market. We came up with a list of the top 20 healthcare companies in the United States. In this blog, we’ll provide update on: What are the top 20 healthcare companies in the United States?
How are they performing?
Will they continue to evolve and scale?
How to reach out to the healthcare companies in the USA(if needed)? We promise to update the list with the current data as and when the USA healthcare market dynamics alters. Moreover, the healthcare companies mentioned below are registered under the pertinent United States laws(for setting up a business).
The above graph clearly indicates Eli Lilly performance has been increasing over the years. The annual gross profit for 2022 was $21.912B, indicating 4.31% increases from 2021. In 2023, it was $ 27.042, a 23.41% increase from 2022. In 2024, it was approximately $36.642, a 35.44% increase from 2023. Additionally for the quarter ending March 31, 2025, the gross profit has almost reached $10B+. This shows a strong uptrend in Eli Lilly and Company performance. Moreover, recently the company announced that they are investing $27 Billion to increase domestic drug production.
The above graph indicates an increase in the company’s growth, starting from 2022 until now. In the year 2022, the annual revenue was $79.99B, a 1.59% increase from 2021. In 2023, it was around $85.159B, a 6.46% increase from 2022. In the year 2024, the annual revenue was $88.821B, a rise by 4.3%. Moreover, until June 30, 2025, the revenue was $23.743B. This shows how the healthcare company (Johnson and Johnson) is evolving at a breakneck speed. The Johnson and Johnson’s MedTech businesses operational sales are expected to grow 5-7% through 2027. Also, Johnson and Johnson’s Innovative Medicine pipeline are projected to deliver 5-7% operational sales growth from 2025-2030. Along with 15+ assets having potential to produce $1-5 billion. The company is developing new pharmaceutical product pipeline, manufacturing drugs to diagnose chronic illness such as Crohn’s disease, cell lung cancer, and more. This represents a rapid expansion of the company.
Talking about the growth cycle, the above graph portrays not much improvement in the annual revenue, although a slight decline is seen. In 2022, the annual revenue was $58.054B, a 3.3 rise from 2021. Coming to 2023, AbbVie annual revenue was $54.318B, indicating a sharp 6.44% decline from the preceding year. In 2024, it was around $56B, slightly higher compared to 2023. In the first quarter of 2025, the annual revenue was $13.34B, comparatively better than the preceding years. AbbVie is facing major setbacks in the 2nd quarter of 2025. It is due to rising R&D expenses, and the decline of its drug Humira. Despite all, the dynamic pipeline is the only ray of hope for AbbVie Inc. bouncing back in the evolving US healthcare market.
The annual revenue for 2022 was $324.162B, a steep 12.71% rise from 2021. In 2023, the annual revenue was around $371.622B, slightly higher than 2022. Therefore, in 2024 it touched $400.278B, the highest of all time. In the first and second quarters of June 2025, it almost reached $111.616B and is expected to surpass $420B. The company has brought multiple surgery centers as well as pharmacies in 2024. It is one of the largest healthcare companies in the US and is growing over the years. Note: If you’re looking to reach out to healthcare professionals from the above-mentioned healthcare companies, contact MedicProspects via email or call. At the end of the blog, you’ll find the MedicProspects email ID and telephone number.
The graph indicates Abbott Laboratories annual revenue in 2022, 2023, and 2024. In 2022, annual revenue = $43.653B, a 1.34% increase from 2021.
2023, annual revenue = $40.109B, 8.12% decline from 2022.
2024, annual revenue = $41.95B, a 4.59% increase from 2023. In the 1st quarter of 2025, it was $10.358B, indicating it would reach $(40-45) B. An uptrend has been observed in the sales of medical devices such as Structural Heart. Also, increase sales in nutrition (global sales of Ensure, the Abott’s best-selling nutrition brand). With the decline of COVID 19, Abbott’s diagnostics business has seen a decline.
The above graph shows slight increase in the annual revenue from 2022 to 2024. Annual Revenue in 2022 = $59.283B, a 21.72% increase from 2021
Annual Revenue in 2023 = $60.115B, a 1.4% increase from 2022, indicating a decline in % increase.
Annual Revenue in 2024 = $64.168B, a 6.74% increase from 2023. In the 1st and 2nd quarter of June, the revenue had only hit $15.806B, signaling a sharp 1.9% decline. The CEO of the company says, they’ll now invest and allocate resources to mature areas of business that would lead to positive growth. He also said with every new product launch, deal closure, etc., the losses will reduce gradually.
In 2022, the annual revenue was approx. $6B, and in 2023, it was $7.124B. For 2024, Intuitive Surgical annual revenue was $8.352B, a 17.24% increase from 2023.
The revenue for the quarter ending March 31, 2025, was $2.253B, a 19.19% increase year-over-year. This shows that the company has growth potential.
The annual revenue of the company from the past 3-4 years has been stable, with slight 0-5% increase/decrease. In 2022, the annual revenue was $44.915B, in 2023 it was approximately $42.857B, and in the year 2024 it was approximately around $42.879B. The company until the first quarter of 2025 achieved $10.364B and is expected to remain constant around $40-43B.
The annual revenue for 2022, 2023, and 2024 is increasing at an increasing rate. For 2022, it was $26B, a 1.32% increase from preceding year. In 2023, the annual revenue was approx. $29B. In 2024, the annual revenue reaches $33.424B, highest of all time. Therefore, it is expected in 2025, the annual revenue will cross $35B.
Compared to 2021, a 6.71% increase was there in annual gross profit for 2022 i.e., $8.726B. 2023, the annual gross profit = $9.895B, a 13.4% rise from the previous year.
2024, the annual gross profit was approximately more than $11B, a 16.12% increase. This clearly shows Boston Scientific is evolving and expanding in terms of gross profit. Also, increasing gross profit indicates an increase in overall business. Additionally, until the first quarter of March,2025, the gross profit is $3.210B, signifying a 21.27% rise over the years.
Considering the metric, annual gross profit, it has shown an increase from the initial years. The recent figure, 2022, the annual gross profit was $11.578B, almost 5% increase from 2021. In 2023, the annual gross profit was $13.058B, double the increase i.e., 12.78% from 2022. In 2024, it was $14.44B, a 10.58% increase from the preceding year. This clearly represents Stryker Corporation is financially stable and profitable.
In 2022, the annual revenue was $26.643B, a 7.42% greater than the preceding year. After that the company witnessed a sharp decline. 2023, the annual revenue went down to $23.89B, a 10.33% decline from the year 2022. Again, in 2024, it was around $23.875B, a 0.05% decline from the preceding year. Additionally, in the first quarter of 2025 i.e., until March 31st, the company achieved only $5.741, again a decline compared to the previous months. The decline in the revenue figure directly signifies the company is financially unstable and operations are inefficient. Still, there’s a slight scope of further improvement.
In 2022, during the widespread of COVID-19, the annual revenue touched $101.175B. Although, as the number of cases declined, Pfizer saw a major decline in its annual revenue around $59.553B, a 41.14% decline from 2022. And then not much but a very slight increase was there in 2024 i.e., $63.62B. Moreover, the first quarter of 2025 witnesses a 7.82% decline. The company needs to improve its product pipeline and focus on different approaches to further gain strong foothold in the US healthcare market.
The annual revenue has mostly been flat. In 2022, $27.281B, almost same as 2021. In the year 2023, the annual revenue was $27.116B, a 0.6% decline from the preceding year. The annual revenue in 2024 was approx. $28.754B, a 6.04% increase from 2023. But again they have seen a decline in the first quarter of 2025, 0.28% decline.
The annual revenue for the year 2022 was $8.931B, you won’t believe it was approximately 17.91% higher than 2021. In 2023, $ 9.869B, a 10.51% increase from 2022. And in the year 2024, the annual revenue was again higher than the preceding years i.e., $11.02B, a 11.66% increase from 2023. Also, the first quarter of 2025 has been good with revenue around $2.77B. This represents significant growth at a faster rate. The company tends to have a huge profit over the years.
The annual revenue of 2022 was $46.159B, a minimal decline was seen i.e., of 0.49% from 2021. In 2023, the decline continued, the annual revenue became $45.006B, a 2.5% less compared to 2022. In the year 2024, the company witnessed an increase i.e., $48.3B, a 7.32% increase from the preceding year. The first quarter of 2025, the company has reported annual revenue of $12.269B, a 0.56% rise over the years. This shows Bristol-Myers Squibb is financially strong and business has huge scope of improvement.
The above graph shows HCA Healthcare, Inc. is unfolding year-over-years. The annual revenue in 2022 was $60.23B, higher than the preceding year, almost 2.52%. In 2023, it went to $64.968B, a 7.86% more from 2022 and in the year 2024 it touched $70B. Moreover, in the 1st quarter of 2025, it has already reached $18B, and the annual revenue is projected around $72B or more. This clearly shows how rapidly the company is evolving by providing specialized healthcare services and solutions.
The graphs indicate the annual revenue for the past 3-4 years. It has been increasing at an increasing rate. 2022, the annual revenue was $263.966B, much higher compared to 2021. In 2023, it was approx. $276B, the percentage increase was 4.83%. In 2024, the annual revenue was $308B, 11.65% more than 2023. In 2025, until the first quarter Mckesson achieved $90B, and is expected to reach $359B, a 16.22% increase from 2024. This shows how the company’s revenue is increasing over the years, highlighting huge growth potential.
The annual revenue of Cigna Corporation has been continuously increasing over the past years. In 2022, the annual revenue was approx. $180 billion, then in 2023 it increased up to $195B, and in 2024 a drastic change in the annual revenue went up to $247 billion. Moreover, it is expected that the Cigna Group will achieve up to $265B in the current year(2025). This shows the company is already making huge profits, and is expected to grow even much more in the upcoming years.
The annual revenue has shown an uptrend as per the above graph. 2022, the annual revenue was $320 billion, in 2023 it was approx. $355 billion, and in 2024 the annual revenue almost reached $372 billion. It is expected the annual revenue will reach $385 billion or more in the current year i.e., 2025.
Highlighting the top Healthcare Companies in the USA
1. Eli Lilly and Company
Did you know? Eli Lilly and Company is the best manufacturers of medicines. Their medicine helps to fight against chronic diseases prevailing globally. They have developed medicines to deal with conditions such as: Alzheimer Cancer Diabetes Being one of the top medicine companies, in 2020 they provided testing facilities, PPE supplies, and developed biological treatments for COVID-19. Founder- Eli Lilly
- Indianapolis, Indiana, U.S.
- US$45.04 billion (2024)
- 47,000 (2024)
The above graph clearly indicates Eli Lilly performance has been increasing over the years. The annual gross profit for 2022 was $21.912B, indicating 4.31% increases from 2021. In 2023, it was $ 27.042, a 23.41% increase from 2022. In 2024, it was approximately $36.642, a 35.44% increase from 2023. Additionally for the quarter ending March 31, 2025, the gross profit has almost reached $10B+. This shows a strong uptrend in Eli Lilly and Company performance. Moreover, recently the company announced that they are investing $27 Billion to increase domestic drug production.2. Johnson & Johnson
About the Company: It is one of the largest American multinational healthcare companies. It deals in three aspects of healthcare:- Pharmaceuticals
- Biotechnology
- Medtech
- Robert Wood Johnson I
- James Wood Johnson
- Edward Mead Johnson
- Johnson and Johnson Plaza, New Brunswick, New Jersey, U.S.
- US$88.82 billion (2024)
- 138,100 (2024)
The above graph indicates an increase in the company’s growth, starting from 2022 until now. In the year 2022, the annual revenue was $79.99B, a 1.59% increase from 2021. In 2023, it was around $85.159B, a 6.46% increase from 2022. In the year 2024, the annual revenue was $88.821B, a rise by 4.3%. Moreover, until June 30, 2025, the revenue was $23.743B. This shows how the healthcare company (Johnson and Johnson) is evolving at a breakneck speed. The Johnson and Johnson’s MedTech businesses operational sales are expected to grow 5-7% through 2027. Also, Johnson and Johnson’s Innovative Medicine pipeline are projected to deliver 5-7% operational sales growth from 2025-2030. Along with 15+ assets having potential to produce $1-5 billion. The company is developing new pharmaceutical product pipeline, manufacturing drugs to diagnose chronic illness such as Crohn’s disease, cell lung cancer, and more. This represents a rapid expansion of the company.3. AbbVie Inc.
About the Company: Currently, AbbVie Inc. caters to manufacturing, developing, and creating innovative medicines and healthcare solutions that cure chronic illness. Aim: To address complex health issues, solve them, and make individuals’ lives healthy across the world. Going forward, they are also building a pipeline of new medicines to find treatments for new ailments (if any). Key people- Richard A. Gonzalez (chairman)
- Robert Michael (CEO)
- 1 North Waukegan Road, North Chicago, Illinois, United States
- US$56.33 billion (2024)
- 55,000 (2024)
Talking about the growth cycle, the above graph portrays not much improvement in the annual revenue, although a slight decline is seen. In 2022, the annual revenue was $58.054B, a 3.3 rise from 2021. Coming to 2023, AbbVie annual revenue was $54.318B, indicating a sharp 6.44% decline from the preceding year. In 2024, it was around $56B, slightly higher compared to 2023. In the first quarter of 2025, the annual revenue was $13.34B, comparatively better than the preceding years. AbbVie is facing major setbacks in the 2nd quarter of 2025. It is due to rising R&D expenses, and the decline of its drug Humira. Despite all, the dynamic pipeline is the only ray of hope for AbbVie Inc. bouncing back in the evolving US healthcare market.4. UnitedHealth Group Incorporated
About the Company: UnitedHealth Groups is a multinational profit-driven company. It exclusively deals with two things: Health Insurance Health Care Services It has two complementary businesses – Optum and UnitedHealthcare – both working to provide effective/robust health system. The main services are: healthcare services, health insurance, health care provider. Founder- Richard T. Burke
- Eden Prairie, Minnesota, United States
- US$400.3 billion (2024)
- 400,000 (2024)
The annual revenue for 2022 was $324.162B, a steep 12.71% rise from 2021. In 2023, the annual revenue was around $371.622B, slightly higher than 2022. Therefore, in 2024 it touched $400.278B, the highest of all time. In the first and second quarters of June 2025, it almost reached $111.616B and is expected to surpass $420B. The company has brought multiple surgery centers as well as pharmacies in 2024. It is one of the largest healthcare companies in the US and is growing over the years. Note: If you’re looking to reach out to healthcare professionals from the above-mentioned healthcare companies, contact MedicProspects via email or call. At the end of the blog, you’ll find the MedicProspects email ID and telephone number.5. Abbott Laboratories
About the Company: They are multinational healthcare company specializing in developing and producing medical devices and branded pharmaceuticals. The devices and pharmaceuticals developed by Abbott Laboratories helps in: Diabetes Management Diagnostic Testing Cardiovascular Health Chronic Pain Aim: To ensure individuals stays healthy throughout their life. Founder- Wallace Calvin Abbott
- Abbott Park, Illinois, U.S.
- US$41.9 billion (2024)
- 114,000 (2024)
The graph indicates Abbott Laboratories annual revenue in 2022, 2023, and 2024. In 2022, annual revenue = $43.653B, a 1.34% increase from 2021.
2023, annual revenue = $40.109B, 8.12% decline from 2022.
2024, annual revenue = $41.95B, a 4.59% increase from 2023. In the 1st quarter of 2025, it was $10.358B, indicating it would reach $(40-45) B. An uptrend has been observed in the sales of medical devices such as Structural Heart. Also, increase sales in nutrition (global sales of Ensure, the Abott’s best-selling nutrition brand). With the decline of COVID 19, Abbott’s diagnostics business has seen a decline.6. Merck & Co., Inc.
A biopharmaceutical firm, known as MSD in every nook and corner of the globe excluding USA and Canada. Aim: To offer top notch health solutions for both humans and animals suffering globally. Curing and treating diseases is what they strive for every day. Founders- Theodore Weicker
- George Merck
- Rahway, New Jersey, U.S.
- US$64.17 billion (2024)
- 75,000 (2024)
The above graph shows slight increase in the annual revenue from 2022 to 2024. Annual Revenue in 2022 = $59.283B, a 21.72% increase from 2021
Annual Revenue in 2023 = $60.115B, a 1.4% increase from 2022, indicating a decline in % increase.
Annual Revenue in 2024 = $64.168B, a 6.74% increase from 2023. In the 1st and 2nd quarter of June, the revenue had only hit $15.806B, signaling a sharp 1.9% decline. The CEO of the company says, they’ll now invest and allocate resources to mature areas of business that would lead to positive growth. He also said with every new product launch, deal closure, etc., the losses will reduce gradually.7. Intuitive Surgical, Inc.
An American biotechnology organization that develops, produces, and manufactures robotic products. They are pioneers in robotic-assisted surgery, offering innovative healthcare solutions. The manual treatment given by surgeons are enhanced with the support of these robotic healthcare devices. This makes the chances of survival a little higher, ensuring people live a healthy life. Headquarters Sunnyvale, California, U.S. Key people- Gary S. Guthart (chairman)
- Dave Rosa (CEO)
- Craig Barratt (Board Member)
- US$18.7 billion (2024)
- 15,638 (2024)
In 2022, the annual revenue was approx. $6B, and in 2023, it was $7.124B. For 2024, Intuitive Surgical annual revenue was $8.352B, a 17.24% increase from 2023.
The revenue for the quarter ending March 31, 2025, was $2.253B, a 19.19% increase year-over-year. This shows that the company has growth potential.8. Thermo Fisher Scientific Inc.
They deal in two major things: Scientific and medical instruments Across the global, if any country is looking for medical instruments, laboratory equipment, consumables, chemicals, and biotechnology services, Thermos Fisher fulfill all needs. Headquarters- Waltham, Massachusetts, U.S.
- Marc N. Casper (chairman, president & CEO)
- Michel Lagarde (COO)
- Ryan Snyder (CIO)
- US$97.3 billion (2024)
- 125,000 (2024)
The annual revenue of the company from the past 3-4 years has been stable, with slight 0-5% increase/decrease. In 2022, the annual revenue was $44.915B, in 2023 it was approximately $42.857B, and in the year 2024 it was approximately around $42.879B. The company until the first quarter of 2025 achieved $10.364B and is expected to remain constant around $40-43B.9. Amgen Inc.
Both Merck & Co., Inc. and Amgen Inc. are a pharmaceutical company with the only difference in the former developing medicines for both humans and animals, but the latter manufactures high-quality medicines to aid millions of people fighting against chronic illness. The company is present in 100 geographies, with the motive to ensure individuals live longer and happier lives. Headquarters- Thousand Oaks, California, U.S.
- Robert A. Bradway (chairman, president & CEO)
- US$91.8 billion (2024)
- 28,000 (2024)
The annual revenue for 2022, 2023, and 2024 is increasing at an increasing rate. For 2022, it was $26B, a 1.32% increase from preceding year. In 2023, the annual revenue was approx. $29B. In 2024, the annual revenue reaches $33.424B, highest of all time. Therefore, it is expected in 2025, the annual revenue will cross $35B.10. Boston Scientific Corporation
About the Company: It is an American biomedical and biotechnology firm that develops, manufactures and markets devices for number of interventional medical specialties. Boston Corp. has manufacturing facilities in the US, Ireland, Costa Rica, Brazil, Malaysia and Puerto Rico. Founders- John Abele
- Peter Nicholas
- Marlborough, Massachusetts, U.S.
- US$39.39 billion (2024)
- 53,000 (2024)
Compared to 2021, a 6.71% increase was there in annual gross profit for 2022 i.e., $8.726B. 2023, the annual gross profit = $9.895B, a 13.4% rise from the previous year.
2024, the annual gross profit was approximately more than $11B, a 16.12% increase. This clearly shows Boston Scientific is evolving and expanding in terms of gross profit. Also, increasing gross profit indicates an increase in overall business. Additionally, until the first quarter of March,2025, the gross profit is $3.210B, signifying a 21.27% rise over the years.11. Stryker Corporation
An American multinational healthcare corporation specializing in producing medical equipment and devices that require effective technology. They also offer healthcare services to treat specific diseases. Unique products and services are: Surgical Equipment Neurotechnology Trauma Surgeries Aim: To make healthcare better for improving patient health. Founder- Homer Stryker
- Kalamazoo, Michigan, U.S.
- Newbury, Berkshire, U.K.
- US$42.97 billion (2024)
- 53,000 (2024)
Considering the metric, annual gross profit, it has shown an increase from the initial years. The recent figure, 2022, the annual gross profit was $11.578B, almost 5% increase from 2021. In 2023, the annual gross profit was $13.058B, double the increase i.e., 12.78% from 2022. In 2024, it was $14.44B, a 10.58% increase from the preceding year. This clearly represents Stryker Corporation is financially stable and profitable.12. Danaher Corporation
An American healthcare company specializing in three things: Biotechnology Diagnostics Life Sciences The main aim is to utilize the power of science and technology in the healthcare industry. “Make human health better and improve the quality of life across every nook and corner of the world.” Founders- Steven Rales
- Mitchell Rales
- Washington, D.C., U.S.
- US$77.5 billion (2024)
- 63,000 (2024)
In 2022, the annual revenue was $26.643B, a 7.42% greater than the preceding year. After that the company witnessed a sharp decline. 2023, the annual revenue went down to $23.89B, a 10.33% decline from the year 2022. Again, in 2024, it was around $23.875B, a 0.05% decline from the preceding year. Additionally, in the first quarter of 2025 i.e., until March 31st, the company achieved only $5.741, again a decline compared to the previous months. The decline in the revenue figure directly signifies the company is financially unstable and operations are inefficient. Still, there’s a slight scope of further improvement.13. Pfizer Inc.
In 2022, during the widespread of COVID-19, the annual revenue touched $101.175B. Although, as the number of cases declined, Pfizer saw a major decline in its annual revenue around $59.553B, a 41.14% decline from 2022. And then not much but a very slight increase was there in 2024 i.e., $63.62B. Moreover, the first quarter of 2025 witnesses a 7.82% decline. The company needs to improve its product pipeline and focus on different approaches to further gain strong foothold in the US healthcare market.14. Gilead Sciences, Inc.
A drug manufacturing company working day and night in researching and manufacturing medicines that treats fatal diseases such as HIV/AIDS, hepatitis B, hepatitis C. Aim: To give hope to people globally that they can fight against such non-curable diseases, and live a healthy life. Founder- Michael L. Riordan
- Foster City, California, United States
- US$58.99 billion (2024)
- 17,600 (2024)
The annual revenue has mostly been flat. In 2022, $27.281B, almost same as 2021. In the year 2023, the annual revenue was $27.116B, a 0.6% decline from the preceding year. The annual revenue in 2024 was approx. $28.754B, a 6.04% increase from 2023. But again they have seen a decline in the first quarter of 2025, 0.28% decline.15. Vertex Pharmaceuticals Incorporated
About the Company: It is an American biotechnology company that develops medicines for individuals dealing with life-threating and chronic ailments. The company research, discover, and develops small molecule drugs for treatment of fatal diseases. The main aim is to make people’s lives better. Founder- Josh Boger
- Boston, Massachusetts, U.S.
- US$22.53 billion (2024)
- 6,100 (2024)
The annual revenue for the year 2022 was $8.931B, you won’t believe it was approximately 17.91% higher than 2021. In 2023, $ 9.869B, a 10.51% increase from 2022. And in the year 2024, the annual revenue was again higher than the preceding years i.e., $11.02B, a 11.66% increase from 2023. Also, the first quarter of 2025 has been good with revenue around $2.77B. This represents significant growth at a faster rate. The company tends to have a huge profit over the years.16. Bristol-Myers Squibb Company
They are pharma company giants specializing biopharmaceutical products:- Research
- Discovery
- Development
- Manufacturing
- Commercializing
- William McLaren Bristol
- John Ripley Myers
- E. R. Squibb
- Princeton, New Jersey, U.S. (registered)
- Lawrenceville, New Jersey, U.S. (corporate)
- US$92.6 billion (2024)
- 34,100 (2024)
The annual revenue of 2022 was $46.159B, a minimal decline was seen i.e., of 0.49% from 2021. In 2023, the decline continued, the annual revenue became $45.006B, a 2.5% less compared to 2022. In the year 2024, the company witnessed an increase i.e., $48.3B, a 7.32% increase from the preceding year. The first quarter of 2025, the company has reported annual revenue of $12.269B, a 0.56% rise over the years. This shows Bristol-Myers Squibb is financially strong and business has huge scope of improvement.17. HCA Healthcare, Inc.
About the Company: It is American company offering premium healthcare facility across the USA and Uk. The company’s goal is to provide top-notch service to people facing any kind of illness, ensuring every day they feel 1% healthier. Founders- Thomas F. Frist Sr.
- Thomas F. Frist Jr.
- Jack C. Massey
- Nashville, Tennessee, U.S.
- US$3.759 billion (2020)
- 309,000 (2024)
The above graph shows HCA Healthcare, Inc. is unfolding year-over-years. The annual revenue in 2022 was $60.23B, higher than the preceding year, almost 2.52%. In 2023, it went to $64.968B, a 7.86% more from 2022 and in the year 2024 it touched $70B. Moreover, in the 1st quarter of 2025, it has already reached $18B, and the annual revenue is projected around $72B or more. This clearly shows how rapidly the company is evolving by providing specialized healthcare services and solutions.18. McKesson Corporation
About the Company: It is an American healthcare supplies distributing company. It primarily deals in three categories such as: U.S. Pharmaceutical Medical-Surgical Solutions Prescription Technology Solutions Mckesson Corp. aim is to advance the healthcare sector and offer better solutions. Founders- John McKesson
- Charles M. Olcott
- Irving, Texas, U.S.
- US$75.1 billion (2025)
- 45,000 (2025)
The graphs indicate the annual revenue for the past 3-4 years. It has been increasing at an increasing rate. 2022, the annual revenue was $263.966B, much higher compared to 2021. In 2023, it was approx. $276B, the percentage increase was 4.83%. In 2024, the annual revenue was $308B, 11.65% more than 2023. In 2025, until the first quarter Mckesson achieved $90B, and is expected to reach $359B, a 16.22% increase from 2024. This shows how the company’s revenue is increasing over the years, highlighting huge growth potential.19. Cigna Corporation
An American multinational company dealing in two categories: Healthcare Solutions Insurance Company’s aim is to enhance the health and lives of those who are in need. Headquarters- Bloomfield, Connecticut, U.S.
- David Cordani (chairman and CEO)
- Brian Evanko (COO)
- US$155.9 billion (2024)
- 73,500 (2024)
The annual revenue of Cigna Corporation has been continuously increasing over the past years. In 2022, the annual revenue was approx. $180 billion, then in 2023 it increased up to $195B, and in 2024 a drastic change in the annual revenue went up to $247 billion. Moreover, it is expected that the Cigna Group will achieve up to $265B in the current year(2025). This shows the company is already making huge profits, and is expected to grow even much more in the upcoming years.20. CVS Health Corporation
About the Company: It is an American healthcare company that owns multiple sub-companies under it. The CSV Pharmacy, i.e., the retail pharmacy chain in the USA. The CSV Caremark, i.e., the pharmacy benefit manager Th Aetna, a health insurance provider and many more! The company’s aim is to put medicines and wellness within the reach of people. Founders- Stanley P. Goldstein
- Sidney Goldstein
- Ralph P. Hoagland III
- Woonsocket, Rhode Island, U.S.
- US$253.2 billion (2024)
- 300,000 (2024)
The annual revenue has shown an uptrend as per the above graph. 2022, the annual revenue was $320 billion, in 2023 it was approx. $355 billion, and in 2024 the annual revenue almost reached $372 billion. It is expected the annual revenue will reach $385 billion or more in the current year i.e., 2025.Looking to Connect with the Above-Mentioned USA Healthcare Companies?
Yes, that’s possible! MedicProspects. a B2B healthcare data provider offers contact information of healthcare professionals operating in multiple geographies and healthcare companies. So, if you’re looking to build business connections with medical directors, CEOs, physicians, nurses, etc., from Eli Lilly, Abbot Laboratories, Johnson & Johnson, etc. Contact MedicProspects via email/call. Using our accurate and verified contact database, you can reach out to your target professionals, connect with them, and sell your products/services easily. So why wait? Reach out to us! Email: [email protected] Call: +1 302-204-1434Conclusion
Research says over the next 10 years the United States healthcare industry will grow, expand, and scale. This indicates a window of opportunity for businesses seeking to enter and establish in the US healthcare landscape. So, if you’re a pharmaceutical firm, medical device manufacturer, health tech provider, etc., setting up your business in the USA would be strategic and lucrative approach. In this blog, we’ve clearly mentioned the top 20 healthcare companies established in the United Sates along with its specifics. Such as headquarters, asset size, annual revenue, gross profit, and more. Are you looking forward to becoming one among the 20 healthcare companies mentioned above? Get the best solution/advice from MedicProspects team on how to easily and effectively tap the USA healthcare market.